



Breaking down boundaries with our new biologics manufacturing site

Located in New Jersey, USA

www.enzene.com



Passion. Innovation. Life.

Welcome to Enzene's state-of-the-art manufacturing site

Our first manufacturing site in New Jersey is at the heart of the US Northeast Corridor, providing easy access for many of our customers, and positioning us in a prime location for forming partnerships with new companies.

Spread over 80,000 sq ft, this plant holds the distinction of being one of the only biologics-focused fully-connected continuous manufacturing™ (FCCM™) facilities based in the U.S.

The site will also host multiple processing lines of our fully-connected continuous manufacturing technology, EnzeneX™.

'Bringing our patented and innovative technology into North America will help to streamline supply chains, accelerate turnaround times, and provide greater control of the overall manufacturing process, hosted under one roof.'

Everything you need in a partner

We understand the unique challenges faced by small and mid-sized biotech companies in securing clinical phase and commercial capacity for their novel molecules. Our state-of-the-art facility is here to cater specifically to your needs.

New Jersey is ideal for us to serve emerging innovative, US-based biotech firms looking to benefit from our in-depth expertise in continuous manufacturing. This expansion marks a significant milestone in our commitment to delivering affordable and innovative solutions that positively impact the global healthcare ecosystem.

We are committed to bringing the best to your project, comprising a world-class team with deep scientific and technical expertise across a wide range of modalities. New Jersey offers an abundant pool of highly skilled talent, which will ensure that we have the resources we need to achieve the full potential of your product.


We are confident that this expansion enables us to continue providing our clients with the exceptional manufacturing services they have come to expect from Enzene.



EnzeneX™, hosted at this site, utilizes our fully-connected continuous manufacturing™ technology to optimize quality, efficiency and flexibility, ensuring maximum value is delivered. It also supports the cost-effective, and sustainable production of high-quality biologics, making them more accessible to patients worldwide. With multiple manufacturing lines at the site, we are poised to meet the growing demand for biologics and biosimilars in the US.



Our patented and validated fully-connected continuous manufacturing™ technology



EnzeneX™ delivers higher productivity, quality, and sustainability at a significant cost advantage



Fully validated method

Proven manufacture of commercial mAbs and conversion of biologics from fed batch to fully-connected continuous manufacturing™



Increased productivity

Upstream processing productivity is increased by up to 10x



Cost effective manufacturing

A lower cost of goods can translate to a 50% reduction in processing costs




High quality products

Minimized product contact with cell culture fluid reduces aggregation and degradation (clipping, oxidation, deamination, glycation) and means high quality products, even for less-stable and difficult-to-express proteins (fusion proteins, bi/multi-specific antibodies, cytokines)



Flexible design

Clinical phase GMP supply in as low as 30-50L scale and modular design with variable bioreactor capacity accelerates development with scale-on and scale-out approaches



Reduced emissions

Smaller equipment and single-use bioreactors can reduce carbon footprint up to 50%

Enzene's manufacturing powerhouse goes live



- Brownfield development in New Jersey
- 80,000 sq. ft.
- USD 50 million invested



- Multi-staged, phased growth
- Phase 1 launch – Sep, 2025
- 70 employees by end of 2025



- Drug Substance
- Drug Product
- CMC

We offer modular and flexible manufacturing capacity in the US



2
Bioreactors (2X500L)



2
Manufacturing suites



CHO GMP-grade modality agnostic
manufacturing (mAbs, recombinant proteins, fusion proteins, bispecific proteins)



Clinical and phase GMP supply
using fed-batch and FCCM™



4
additional DS suites (500L, 1000L & 2000L) in the near future, with the possibility of a drug product filling line



EnzeneX™
Scale-on and scale-out

US site capabilities – Phase 1



Process development capabilities

- Upstream process development (5L, 10L, 50L)
- Downstream process development
- Supporting analytical studies



Manufacturing capabilities

- 2 suites
- Separate media & buffer preparation
- 2x500L bioreactors (Fed Batch & FCCM™)
- Viral segregation
- Drug substance filling and storage



Analytical development & quality control



Supporting capabilities

- Segregated / dedicated AHUs
- WFI generation & distribution
- Biowaste & waste neutralization
- Clean compressed air & process gases

Our analytical and quality control capabilities are there when you need them



Phase 1 site development

- Technology Transfer
- Raw material, in-process and finished product testing
- Impurity profiling
- Identity and potency testing
- Protein characterization
- Microbiology testing



Phase 2 site development

- Method validation and stability testing for all your regulatory needs from FDA to EMEA and the rest of the world



Supporting capabilities

- Efficacy serial
- Cell banking

What does the future hold?

The launch of our New Jersey site coincides with our ambitious expansion plans and will play a central role in our future growth. This expansion into North America enhances our manufacturing capabilities to better serve North American companies and facilitate faster delivery of products to the market. This growth will pave the way toward achieving our objective of increasing healthcare accessibility, leading to better patient outcomes.


Our mission is to provide affordable, quality medicine to aid human and animal lives with debilitating conditions

We have always been committed to delivering trusted and affordable solutions that can positively impact the global healthcare ecosystem. Enzene's onshoring of manufacturing capacities at the New Jersey plant ensures access equity for early-stage biological assets by providing cost-effective, yet quality local manufacturing.



Discover how we could support you at our **United States facility**

Values



Mission

Broadening our innovative technology platforms with emerging modalities in India & US, to enable accelerated development from concept to commercialization for our CDMO partners

Enhancing our manufacturing facilities and quality management system to meet evolving global quality standards

Scaling up our systems, processes and platforms for sustainable business growth

Being the most desired biotech company to work for by creating an unparalleled work culture and meaningful careers for our employees

Establish as a global biosimilar company through timely launches of key products in multiple geographical markets

Being a responsible corporate citizen on all aspects of environment, health and safety

Get in touch at:
www.enzene.com/contact-us
bd@enzene.com



Global R&D and Manufacturing*, Pune, India

*Our microbial and mammalian DS plants as well as our sterile fill & finish plant have received EU-GMP certification



USDA Designed Facility, New Jersey, USA



Passion. Innovation. Life.



enze.com